CG'806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3.

被引：0
|
作者：
Zhang, Weiguo [1 ]
Zhang, Hongying [2 ]
Local, Andrea [2 ]
Rice, William G. [2 ]
Ly, Charlie J. [1 ]
Yu, Guopan [1 ]
Howell, Stephen B. [3 ]
Andreeff, Michael [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Aptose Biosci, San Diego, CA USA
[3] UCSD Canc Ctr, La Jolla, CA USA
来源：
CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [1] CG′806, a First-in-Class FLT3/BTK Inhibitor, Exerts Superior Potency against AML Cells Harboring ITD, TKD and Gatekeeper Mutated FLT3 or Wild-Type FLT3
    Zhang, Weiguo
    Zhang, Hongying
    Local, Andrea
    Rice, Wiliam
    Ly, Charlie
    Yu, Guopan
    Howell, Stephen
    Andreeff, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S274 - S275
  • [2] CG'806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes.
    Kurtz, Stephen E.
    Wilmot, Beth
    McWeeney, Shannon
    Vellanki, Avanish
    Local, Andrea
    Benbatoul, Khalid
    Folger, Peter
    Sheng, Susan
    Zhang, Hongying
    Howell, Stephen B.
    Rice, William G.
    Druker, Brian J.
    Tyner, Jeffrey W.
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 62 - 63
  • [3] Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
    Chen, Fangli
    Ishikawa, Yuichi
    Akashi, Akimi
    Naoe, Tomoki
    Kiyoi, Hitoshi
    ONCOTARGET, 2016, 7 (30) : 47018 - 47032
  • [4] CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples
    Kurtz, Stephen E.
    Watanabe-Smith, Kevin
    Bottomly, Dan
    Wilmot, Beth
    Mcweeney, Shannon
    Local, Andrea
    Zhang, Hongying
    Howell, Stephen
    Rice, William
    Druker, Brian J.
    Tyner, Jeffrey W.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations
    Alvarado, Yesid
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Luthra, Rajyalakshmi
    Borthakur, Gautam
    Manero, Guillermo Garcia
    Faderl, Stefan
    Konopleva, Marina
    Estrov, Zeev
    Andreeff, Michael
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 648 - 648
  • [6] FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells
    Jetani, Hardikkumar
    Garcia-Cadenas, Irene
    Nerreter, Thomas
    Goetz, Ralph
    Sierra, Jorge
    Bonig, Halvard
    Sauer, Markus
    Einsele, Hermann
    Hudecek, Michael
    BLOOD, 2018, 132
  • [7] Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics
    Kellner, Fabienne
    Keil, Andreas
    Schindler, Katrin
    Tschongov, Todor
    Huenninger, Kerstin
    Loercher, Hannah
    Rhein, Peter
    Boehmer, Sylvia-Annette
    Boehmer, Frank-D.
    Mueller, Joerg P.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (08) : 4668 - 4676
  • [8] Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation
    Heng, Hao
    Zhi, Yanle
    Yuan, Haoliang
    Wang, Zhijie
    Li, Hongmei
    Wang, Shuxian
    Tian, Jieyi
    Liu, Haichun
    Chen, Yadong
    Lu, Tao
    Ran, Ting
    Lu, Shuai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 163 : 195 - 206
  • [9] Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy
    Zhang, Weiguo
    Yu, Guopan
    Zhang, Hongying
    Ly, Charlie
    Yuan, Bin
    Ruvolo, Vivian
    Piya, Sujan
    Bhattacharya, Seemana
    Zhang, Qi
    Borthakur, Gautam
    Battula, Venkata Lokesh
    Konopleva, Marina Y.
    Rice, William G.
    Andreeff, Michael
    BLOOD, 2018, 132
  • [10] CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells
    Zhang, Hongying
    Local, Andrea
    Benbatoul, Khalid
    Folger, Peter
    Sheng, Susan
    Tsai, Cheng-Yu
    Howell, Stephen
    Rice, William
    BLOOD, 2017, 130
12345